Major Biosimilar Patent Issues Are Coming to the Boil in the US — Here’s What You Need to Know (Intellectual Asset Management)

With the first US patent litigation involving a biosimilar product being filed as recently as 2014, the strategic playbook for disputes under the Biologics Price Competition and Innovation Act framework is still being written and a number of legal questions remain wide open. Goodwin IP Litigation partner Alexandra Valenti, who just worked to publish the 2020-2021 edition of its Guide to Biosimilars Litigation and Regulation in the US, agrees that it may be a wait to see what the new administration and Congress are going to do. Read the Intellectual Asset Management article here.